08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

ALF-5755: Phase II data

A double-blind, European Phase II trial in 57 patients with HBV- and autoimmune-related acute-on-chronic liver disease or acute liver disease showed that 10 mg IV ALF-5755 every 12 hours for 3 days missed the primary...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Clinical News

rhHIP/PAP regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Alfact's rhHIP/PAP to treat acute liver failure. The recombinant human hepatocarcinoma-intestine-pancreas and pancreatic associated protein will begin Phase...